Amarin (AMRN)
(Delayed Data from NSDQ)
$0.91 USD
-0.01 (-0.87%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 81 - 100 ( 355 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Patent Appeal Hearing Does Not Inspire Confidence
Provider: Oppenheimer & Co. Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Panel Affirms Ruling Invalidating Vascepa IP In The US; Focus Shifts To EU But Surprised Mgmt Not Looking To Cut Costs Now
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Following Affirmation of Patent Invalidation, Focus is on the EU Vascepa Opportunity
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Prospects for CAFC Reversal Dampened - Outperform Rating Remains Intact
Provider: Northland Capital Markets
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Battle Didn''t Go as Planned but the War is Far from Over
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Color From Appeal Hearing Incrementally Negative For AMRN, In Our View; We Are Staying On The Sidelines
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Consultant Affirms Judges Were Tough, Remain HOLD Though US Now Priced Out...
Provider: Jefferies & Company
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Federal Appeals Decision Expected as Soon 2020, Pushing Forward With European Impetus; PT Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Key Paper by REDUCE-IT PI Points to Another Flaw in Ruling vs. Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Spotlight Is on Vascepa and CV Risk in the Face of COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y